Loading clinical trials...
Loading clinical trials...
A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma
Conditions
Interventions
eryaspase
Gemcitabine plus Abraxane
+1 more
Locations
16
United States
Arizona Cancer Center
Scottsdale, Arizona, United States
St. Joseph Heritage Healthcare
Fullerton, California, United States
University of California Davis Medical Center
Sacramento, California, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
Boca Raton Regional Hospital
Boca Raton, Florida, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Start Date
September 15, 2018
Primary Completion Date
August 30, 2021
Completion Date
January 18, 2022
Last Updated
October 18, 2022
NCT07409272
NCT04605913
NCT06998940
NCT06778863
NCT06381154
NCT07148128
Lead Sponsor
ERYtech Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions